Expertise in
24
conditions

Dr. Maria Fleseriu

Endocrinology
OHSU Hospital
3181 SW Sam Jackson Park Rd, 
Portland, OR 
Offers Telehealth
Expertise in
24
conditions
OHSU Hospital
3181 SW Sam Jackson Park Rd, 
Portland, OR 

Overview

Maria Fleseriu is an Endocrinologist practicing medicine in Portland, Oregon.

Dr. Fleseriu is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Acromegaly, Cushing's disease, Cushing's syndrome, Acromegaloid Facial Appearance Syndrome, and Hormone Replacement Therapy (HRT).

She is actively involved in clinical research, co-authoring 274 peer reviewed articles and participating in 7 clinical trials.

Specialties

Endocrinology

Licenses

Internal Medicine in OR

Hospital Affiliations

Ohsu Hospital And Clinics

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
AllCare Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser
  • EPO
  • HMO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
OHSU Health
  • MANAGED MEDICAID PLAN
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Samaritan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

OHSU Hospital
3181 SW Sam Jackson Park Rd, Portland, OR 97239
Other Locations
University Andrology Lab LLC
3303 S Bond Ave, Portland, OR 97239

Additional Areas of Focus

Dr. Fleseriu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Hypoparathyroidism
Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drug: Levoketoconazole
Study Phase: Phase 3
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat
Enrollment Status: Completed
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drug: Osilodrostat
Study Phase: Phase 2
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: November 08, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: November 01, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome
Enrollment Status: Terminated
Publish Date: March 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Enrollment Status: Completed
Publish Date: January 06, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

274 Total Publications

Correction to: Consensus and Controversies about Diagnosing GH deficiency - A Delphi Survey by the GH Research Society.
Correction to: Consensus and Controversies about Diagnosing GH deficiency - A Delphi Survey by the GH Research Society.
Journal: Pituitary
Published: July 27, 2026
Similar Doctors
Expertise in
27
conditions
Dr. Elena V. Varlamov
Endocrinology
Expertise in
27
conditions
Dr. Elena V. Varlamov
Endocrinology
Referral required
Before you request

University Andrology Lab LLC

3303 S Bond Ave, 
Portland, OR 
 (0.7 miles away)
503-494-4314
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elena Varlamov is an Endocrinologist practicing medicine in Portland, Oregon. Dr. Varlamov is highly rated in 27 conditions, according to our data. Her clinical expertise encompasses Prolactinoma, Pituitary Tumor, Acromegaly, and Hypothalamic Tumor. Dr. Varlamov is currently accepting new patients.

Expertise in
9
conditions
Dr. Eric S. Orwoll
Endocrinology
Expertise in
9
conditions
Dr. Eric S. Orwoll
Endocrinology
Referral required

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (0.1 miles away)
503-494-3273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Orwoll is an Endocrinologist practicing medicine in Portland, Oregon. Dr. Orwoll is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Osteoporosis, Osteogenesis Imperfecta, Postmenopausal Osteoporosis, Fractured Spine, and Hormone Replacement Therapy (HRT).

Expertise in
7
conditions
Dr. Paul B. Duell
Endocrinology
Expertise in
7
conditions
Dr. Paul B. Duell
Endocrinology
Referral required
Before you request

OHSU Hospital

3181 SW Sam Jackson Park Rd, 
Portland, OR 
 (0.1 miles away)
503-494-3273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul Duell is an Endocrinologist practicing medicine in Portland, Oregon. Dr. Duell is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Defective Apolipoprotein B-100, Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH), and Heterozygous Familial Hypercholesterolemia (HeFH). Dr. Duell is currently accepting new patients.

Frequently Asked Questions about Dr. Maria Fleseriu

How do I make an appointment with Dr. Maria Fleseriu?

You can book an appointment with Dr. Maria Fleseriu by calling their office at 503-494-8311. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Maria Fleseriu a top-rated expert for Acromegaly?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Maria Fleseriu is classified as an Elite expert for Acromegaly, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Maria Fleseriu specialize in?

While Dr. Maria Fleseriu is a Endocrinology, they have specific expertise in Acromegaly, Cushing's disease, and Cushing's syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Maria Fleseriu participate in research or clinical trials?

Yes. Dr. Maria Fleseriu has published 274 articles and abstracts on conditions like Acromegaly. You can view a list of Dr. Maria Fleseriu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Maria Fleseriu accept my insurance?

Dr. Maria Fleseriu accepts most major insurance plans, including Aetna and AllCare Health. We recommend calling the office directly at 503-494-8311 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fleseriu's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 9 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile